Thurston, Springer, Miller, Herd & Titak, Inc. Acadia Pharmaceuticals Inc Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $730 Million
- Q2 2025
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 53 shares of ACAD stock, worth $1,261. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53Holding current value
$1,261% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ACAD
# of Institutions
352Shares Held
163MCall Options Held
1.77MPut Options Held
307K-
Baker Bros. Advisors LP New York, NY42.9MShares$1.02 Billion8.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.2MShares$362 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$287 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY8.54MShares$203 Million2.32% of portfolio
-
State Street Corp Boston, MA6.99MShares$166 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.85B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...